Hologic Inc. is a global medical technology company focused on improving women's health through the development and delivery of innovative products and solutions. The company specializes in diagnostic, surgical, and medical imaging systems, with a particular emphasis on breast health, cervical health, and skeletal health. Hologic's offerings include advanced molecular diagnostics, imaging systems for breast cancer detection, and various surgical instruments and techniques that enhance patient care. With a commitment to advancing health outcomes for women, Hologic actively invests in research and development to address unmet medical needs and improve access to vital healthcare solutions. Read More
Shares of medical technology company Hologic (NASDAQ:HOLX) jumped 3.1% in the afternoon session after the company announced it agreed to be acquired by private equity firms Blackstone and TPG in a deal that takes the company private.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Hologic, Inc. (NASDAQ: HOLX) to funds managed by Blackstone and TPG is fair to Hologic shareholders. Under the terms of the proposed transaction, Hologic shareholders will receive $76.00 per share in cash plus a non-tradable contingent value right to receive up to $3.00 per share in two payments of up to $1.50 each.
NetworkNewsWire Editorial Coverage : Artificial intelligence (“AI”) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (“WHO”), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American Cancer Society (“ACS”) projects that 316,950 new invasive breast cancer cases will be diagnosed among women this year. The urgent, life-saving need for earlier and more accurate detection creates a powerful opportunity for innovation in diagnostic imaging. Amid this global challenge, companies advancing breast cancer diagnostics are entering a high-impact field. Among them, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) ( profile ) stands out with its next-generation IzoView Breast CT Imaging System, a dedicated 3D imaging platform designed to improve detection accuracy, particularly for women with dense breast tissue. IzoView joins an elite group of companies, including Hologic Inc. (NASDAQ: HOLX), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Nano-X Imaging Ltd. (NASDAQ: NNOX) and Oracle Corp. (NYSE: ORCL), that are focused on playing a….
BALA CYNWYD, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone (“Blackstone”) and TPG in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3 billion.1
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of global alternative asset manager TPG (NASDAQ:TPG) jumped 2.3% in the morning session after reports surfaced that the private equity firm, along with Blackstone, was in advanced negotiations to acquire medical device maker Hologic. The potential take-private deal valued Hologic at more than $17 billion, including debt, with a discussed price above $75 per share. According to people familiar with the matter, the firms had agreed on the terms and lined up the necessary debt financing for what would be one of the year's biggest take-private transactions. The news also caused shares of Hologic to rise.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
While the S&P 500 is up 34.7% since April 2025, Hologic (currently trading at $67.73 per share) has lagged behind, posting a return of 15.9%. This might have investors contemplating their next move.
Clairity Inc. is set to transform the landscape of early breast cancer detection with its groundbreaking AI-powered risk prediction technology, Clairity Breast. Having secured De Novo authorization from the U.S. Food and Drug Administration (FDA) in late May 2025, this innovative platform is the first artificial intelligence tool authorized
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2025 on Monday, November 3, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. The company also announced that the assays obtained CE marking in the European Union in accordance with In Vitro Diagnostic Regulation (IVDR). These highly sensitive molecular tests are designed to rapidly detect the most common bacterial pathogens responsible for infectious gastroenteritis.
Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) will mark the start of Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 19th year. The company will also continue its comprehensive #BustTheMyth patient education campaign following new survey data that shows nearly half of women who are recommended a mammogram either skip or delay the exam.
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc. (NASDAQ: HOLX), to promote Volition’s Nu.Q® Discover service. The program offers drug developers and scientists a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - imaging, diagnostics stocks, including Hologic (NASDAQ:HOLX) and its peers.
Data from two groundbreaking studies evaluating the performance of Hologic’s (Nasdaq: HOLX) artificial intelligence (AI)-powered mammography technology will be presented today at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting in Aberdeen, Scotland.
The healthcare sector stands on the precipice of a monumental transformation, driven by the relentless advance of Artificial Intelligence (AI). From streamlining administrative tasks to enhancing diagnostic accuracy, AI promises a future of more efficient, accessible, and personalized care. However, this technological revolution is not without its complexities, sparking debates
